Treatment with tovecimig, formerly known as CTX-009, elicited responses in patients with biliary tract cancer, according to ...

Eisai’s drug has been submitted for approval on the back of a single-arm phase 2 trial (Study 201) that enrolled patients in Japan and China with FGFR2 gene fusion-positive unresectable biliary ...

Cholestatic liver diseases (CLDs) are a group of disorders characterized by the impairment of bile formation, secretion, or excretion ... types of CLDs are primary biliary cholangitis (PBC ...

Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).

Try it free for 7 days Biliary tract cancer is estimated to affect approximately 23,000 patients annually in the United States. The study enrolled 168 adult patients. All patients were dosed with ...

The Biliary Epigenetics and Regenerative Medicine Lab of Robert C. Huebert, M.D., includes research programs and a biobank containing stem cells from patients with liver disease.

Previous studies of the bile acid composition of meconium and bile obtained in the first few days of life indicate that, compared to the adult, there are significant differences in the hepatic ...